Incyte Corp

Incyte insider trading: EVP Heeson Lee sells 111 shares at $102.67 on Feb 2 2026. The move reflects routine liquidity management amid steady stock gains and strong pipeline prospects—no negative impact on valuation or investor confidence.

Incyte’s insider sale of 8,264 shares is a routine tax move, not a warning. With frontMIND Phase‑III data showing 48% response and 12‑month survival over 80%, the tafasitamab–lenalidomide combo looks ready for FDA review, giving investors and clinic…